Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19
Open Access
- 30 March 2020
- journal article
- review article
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (7), 740-746
- https://doi.org/10.1002/jmv.25798
Abstract
Confronting the challenge of the outbreak of COVID‐19 should sharpen our focus on global drug access as a key issue in anti‐viral therapy testing. The testing and adoption of effective therapies for novel coronaviruses is hampered by the challenge of conducting controlled studies during a state of emergency. The access to direct anti‐viral drugs such as ribavirin that have an existing inventory and reliable supply chain may be a priority consideration for therapies developed for the 2019‐nCoV infection outbreaks and any strain variants that may emerge. Based on the direct anti‐viral activity of ribavirin against 2019‐nCoV in vitro and evidence for potency enhancement strategies developed during the prior SARS and MERS outbreaks, ribavirin may significantly impact our ability to end the lingering outbreaks in China and slow outbreaks in other countries. The apparent COVID‐19 pandemic provides an opportunity to follow dosage guidelines for treatment with ribavirin, test new therapeutic concepts, and conduct controlled testing to apply the scientific rigor required to address the controversy around this mainstay of anti‐viral therapy.This publication has 46 references indexed in Scilit:
- Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirinScientific Reports, 2013
- Ribavirin modulates the conversion of human CD4+ CD25−T cell to CD4+ CD25+ FOXP3+T cell via suppressing interleukin‐10‐producing regulatory T cellImmunology, 2012
- Cell Type Mediated Resistance of Vesicular Stomatitis Virus and Sendai Virus to RibavirinPLOS ONE, 2010
- SARS: Systematic Review of Treatment EffectsPLoS Medicine, 2006
- Mechanisms of action of ribavirin against distinct virusesReviews in Medical Virology, 2005
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004
- Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in CanadaClinical Infectious Diseases, 2003
- Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto AreaJAMA, 2003
- A Major Outbreak of Severe Acute Respiratory Syndrome in Hong KongThe New England Journal of Medicine, 2003
- Identification of Severe Acute Respiratory Syndrome in CanadaThe New England Journal of Medicine, 2003